Chrystal  Jensen net worth and biography

Chrystal Jensen Biography and Net Worth

Insider of Cerus

Ms. Jensen was appointed Chief Legal Officer in 2012. Prior to joining Cerus, Ms. Jensen served as senior corporate counsel at Zynga, Inc. From 2000-2011, she was a partner at Cooley LLP, where she had practiced corporate and securities law. Ms. Jensen received her Juris Doctorate from the University of Chicago and her Bachelor of Science in finance and accounting from the University of Colorado, Boulder.

What is Chrystal Jensen's net worth?

The estimated net worth of Chrystal Jensen is at least $1.73 million as of March 12th, 2025. Ms. Jensen owns 946,131 shares of Cerus stock worth more than $1,731,420 as of March 27th. This net worth evaluation does not reflect any other assets that Ms. Jensen may own. Learn More about Chrystal Jensen's net worth.

How do I contact Chrystal Jensen?

The corporate mailing address for Ms. Jensen and other Cerus executives is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. Cerus can also be reached via phone at (925) 288-6000 and via email at [email protected]. Learn More on Chrystal Jensen's contact information.

Has Chrystal Jensen been buying or selling shares of Cerus?

During the last quarter, Chrystal Jensen has sold $61,998.45 in Cerus stock. Most recently, Chrystal Jensen sold 30,845 shares of the business's stock in a transaction on Friday, March 6th. The shares were sold at an average price of $2.01, for a transaction totalling $61,998.45. Following the completion of the sale, the insider now directly owns 1,059,139 shares of the company's stock, valued at $2,128,869.39. Learn More on Chrystal Jensen's trading history.

Who are Cerus' active insiders?

Cerus' insider roster includes Richard Benjamin (Chief Medical Officer), Eric Bjerkholt (Director), Laurence Corash (Insider), Kevin Green (CFO), William Greenman (CEO), Vivek Jayaraman (COO), Chrystal Jensen (Insider), Ann Lucena (Director), Chrystal Menard (Insider), Carol Moore (SVP), Gail Schulze (Director), Hua Shan (Director), and Daniel Swisher, Jr. (Director). Learn More on Cerus' active insiders.

Are insiders buying or selling shares of Cerus?

In the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 1,194,282 shares worth more than $2,106,289.99. The most recent insider tranaction occured on March, 12th when COO Vivek K Jayaraman sold 165,200 shares worth more than $274,232.00. Insiders at Cerus own 5.6% of the company. Learn More about insider trades at Cerus.

Information on this page was last updated on 3/12/2026.

Chrystal Jensen Insider Trading History at Cerus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2026Sell30,845$2.01$61,998.451,059,139View SEC Filing Icon  
3/12/2025Sell113,008$1.66$187,593.28946,131View SEC Filing Icon  
3/13/2024Sell17,460$2.06$35,967.60508,736View SEC Filing Icon  
See Full Table

Chrystal Jensen Buying and Selling Activity at Cerus

This chart shows Chrystal Jensen's buying and selling at Cerus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cerus Company Overview

Cerus logo
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Read More

Today's Range

Now: $1.83
Low: $1.80
High: $1.91

50 Day Range

MA: $2.20
Low: $1.69
High: $2.62

2 Week Range

Now: $1.83
Low: $1.12
High: $2.96

Volume

870,333 shs

Average Volume

2,443,256 shs

Market Capitalization

$351.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51